Documente Academic
Documente Profesional
Documente Cultură
practica medicală
Allergic rhinitis: from guidelines to
clinical practice
Selda Ali, Elena Cristina Bălă, Larisa Ştefănescu, Sabina-Loredana Corcea
First published: 16 mai 2019
Editorial Group: MEDICHUB MEDIA
DOI: 10.26416/Aler.3.2.2019.2317
Abstract
Allergic rhinitis (AR) is a symptomatic disorder induced by the
hyperreactivity of the nasal mucosa after allergen exposure. Ever
since the first ARIA guideline was published in 2001, the approach
of patients with allergic rhinitis has evolved, thanks to new studies
and new technologies. In the century of computerization, mobile
applications have also emerged in medicine, in order to make life
easier for patients and healthcare professionals. The selection of
pharmacotherapy for the patient with allergic rhinitis depends on
several factors, including age, prominent symptoms, AR control,
patient preferences and cost. In the future, clinical decision support
systems may be a useful tool based on algorithms for choosing the
best treatment for each patient. This article focuses on the current
therapeutic options and the recommendations of the European and
US guidelines.
Keywords
Rezumat
Rinita alergică (RA) este o afecţiune caracterizată prin apariţia de
simptome din cauza hiperreactivităţii mucoasei nazale ca urmare a
expunerii la un alergen sensibilizant. De la apariţia primului ghid
ARIA în 2001, abordarea pacienţilor cu rinită alergică a evoluat,
datorită noilor studii şi noilor tehnologii. În secolul informatizării,
aplicaţiile mobile şi-au făcut loc şi în medicină, cu scopul de a uşura
viaţa pacienţilor şi a personalului medical. Alegerea farmacoterapiei
pentru pacientul cu rinită alergică depinde de mai mulţi factori,
printre care: vârsta, simptomul principal, controlul RA, preferinţele
pacientului şi costul medicaţiei. Sistemele de suport pentru decizia
clinică pot reprezenta în viitor o unealtă bazată pe algoritme, utilă în
alegerea unui tratament optim pentru fiecare pacient. Articolul este
centrat pe opţiunile terapeutice existente în prezent şi pe
recomandările în vigoare ale ghidurilor europene şi americane.
Cuvinte cheie
Bibliografie
1. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al. Allergic
Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol.
2010; 126:466-76.
2. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008
update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy.
2008; 63(Suppl 86):8-160.
3. Brozek JL, Bousquet J, Agache I, Agarwal A, et al. Allergic Rhinitis and its Impact on Asthma
(ARIA) guidelines – 2016 revision. J Allergy Clin Immunol. 2017; 140:950-8.
4. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J
Allergy Clin Immunol. 2001; 108(Suppl. 5):S147– S334.
5. Bousquet J, Schunemann HJ, Samolinski B, Demoly P, et al. Allergic Rhinitis and its Impact on
Asthma (ARIA): Achievements in 10 years and future needs. J Allergy Clin Immunol. 2012;
130:1049-62.
6. Bousquet PJ, Combescure C, Neukirch F, Klossek JM, Mechin H, Daures JP, et al. Visual analog
scales can assess the severity of rhinitis graded according to ARIA guidelines. Allergy. 2007;
62:367–372.
7. Hellings PW, Fokkens WJ, Bachert C, Akdis CA, et al. Positioning the principles of precision
medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA-ARIA-
EPOS-AIRWAYS ICP statement. Allergy. 2017; 72:1297–1305.
8. Bousquet J, Arnavielhe S; MASK study group. MASK 2017: ARIA digitally-enabled, integrated,
person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. Clin Transl
Allergy. 2018; 8:45.
9. Bousquet J, Schunemann HJ, Hellings PW, Arnavielhe S, Bachert C, Bedbrook A, et al.
MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis.
10. J Allergy Clin Immunol. 2016; 138(2):367–74 (e2).
11. Dykewicz MS, Wallace DV, Baroody F, Bernstein J, et al. Treatment of seasonal allergic rhinitis.
An evidence-based focused 2017 guideline update. Ann Allergy Asthma Immunol. 2017; 119;
489e511.
12. Meltzer EO, LaForce C, Ratner P, Price D, Ginsberg D, Carr W. MP29-02 (a novel intranasal
formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal
allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety.
Allergy Asthma Proc. 2012; 33:324e332.
13. Roberts G, Pfaar O, Akdis CA, et al. EAACI Guidelines on Allergen Immunotherapy: Allergic
rhinoconjunctivitis. Allergy. 2018; 73:765–798.
14. Menditto E, Costa E, Midão L, et al., the MASK group. Adherence to treatment in allergic
rhinitis using mobile technology. The MASK Study. Clin Exp Allergy. 2019; 49: 442-460.
15. Duarte Ferreira R, Ornelas C, Silva S, Morgado R, et al. Contribution of In Vivo and In Vitro
Testing for The Diagnosis of Local Allergic Rhinitis. J Investig Allergol Clin Immunol. 2019;
Vol. 29(1): 46-48.